Loading...
•
Dec 31, 2021
4DMT Q4 2021 Earnings Report
Reported full year 2021 financial results and operational highlights, advancing diverse pipeline and achieving key milestones.
Key Takeaways
4D Molecular Therapeutics reported full year 2021 financial results, highlighting clinical data updates on multiple programs, advancement of additional programs into clinical development, and initiation of GMP manufacturing facility expansion. The company's cash, cash equivalents, and investments of $315 million are expected to fund operations into the second half of 2024.
Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies.
Advanced two additional programs into clinical development: R100 vector-based 4D-150 for wet AMD, and A101 vector-based 4D-710 for cystic fibrosis.
Initiated expansion of GMP manufacturing facilities for potential commercial-scale clinical manufacturing capabilities.
Cash, cash equivalents and investments expected to fund operations into the second half of 2024.
4DMT
4DMT
4DMT Revenue by Segment
Revenue by Segment
Collaboration & license rev. Revenue
CapyFin.com Forward Guidance
4DMT anticipates several milestones and objectives for 2022, including first patient dosing in the 4D-710 Phase 1/2 clinical trial for cystic fibrosis expected in the first half of 2022 and continuation of enrollment and follow-up in multiple Phase 1/2 clinical trials.
Positive Outlook
- First patient dosing in the 4D-710 Phase 1/2 clinical trial for cystic fibrosis expected in the first half of 2022
- Continue enrollment and follow-up in both the United States and Asia-Pacific (APAC) Phase 1/2 clinical trials of 4D-310 in Fabry disease
- Continue enrollment and follow-up in the 4D-150 Phase 1/2 clinical trial for wet AMD
- Continue enrollment and follow-up in the Phase 1/2 clinical trials for both 4D-125 for X-linked retinitis pigmentosa and 4D-110 for choroideremia